Dr. Crystal Broussard, MD
Medical Director - Physician Network
Dr. Crystal Broussard serves as the Medical Director for the independent physician network that supports the SimpleCare program. She provides clinical oversight and guidance to ensure patients receive care through licensed healthcare providers.
Patients who use the SimpleCare platform are evaluated by licensed clinicians within the independent physician network who determine treatment eligibility and prescribe medications when medically appropriate.
Dr. Broussard ("Dr. B") is a board-certified medical doctor in Family Medicine and became a fellow of the American Board of Obesity Medicine in 2012. She is also an active member of the Obesity Medical Association and serves on task forces to educate other healthcare professionals on treating obesity.
This site is not part of the Facebook® website or Facebook® Inc. Additionally, this site is not endorsed by Facebook® in any way. Facebook® is the registered trademark of Facebook®, Inc.
SimpleCare (Simple Life, LLC) does not practice medicine or sell prescription medication. Simple Care is a technology platform and referral partner offering access to a licensed physician network.The information provided on this website is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. SimpleCare provides access to a network of licensed healthcare professionals who provide telehealth consultations and medical evaluations. Healthcare services are provided by independent licensed clinicians who exercise their own clinical judgment in evaluating and treating patients. Prescription medications are provided only when deemed medically appropriate by a licensed healthcare provider following a clinical evaluation. Not all patients will qualify for treatment. Individual results may vary. Weight loss results depend on many factors including lifestyle, medical history, adherence to treatment, and other health conditions. All medications carry potential risks and side effects. Patients should discuss potential risks, benefits, and alternatives with their healthcare provider prior to beginning treatment. This website and its services are not intended for medical emergencies. If you are experiencing a medical emergency, call 911 or seek immediate medical attention. The products and statements discussed on this website—excluding prescription medications when true—have not been evaluated by the U.S. Food and Drug Administration (FDA).
Semaglutide, tirzepatide, and other GLP-1 receptor agonist medications may not be approved by the FDA for all uses discussed.
Medications show are for illustrative purposes only.
Important Notes:
-
*Compounded semaglutide is not FDA-approved and the FDA does not evaluate compounded products for safety, effectiveness, or quality. Ozempic® and Wegovy® are not compounded. Ozempic® and Wegovy® are both products and registered trademarks or Novo Nordisk A/S. Ozempic® is FDA-approved for type 2 diabetes but may be prescribed off-label for weight loss per a healthcare practitioner's discretion. Wegovy® is FDA-approved for type 2 diabetes and may be prescribed off-label at a clinician's discretion.
-
*Compounded tirzepatide is not FDA-approved and the FDA does not evaluate compounded products for safety, efficacy or quality. Mounjaro® is FDA-approved for type 2 diabetes and may be prescribed off-label for weight loss per a healthcare practitioner's discretion. Mounjaro® is a product and registered trademark of Eli Lily and Company.